stockrowMARKER THERAPEUTICS, INC.
MRKR Healthcare Biotechnology
MARKER THERAPEUTICS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 46.2% from fiscal 2024.
- Revenue
- −51.0%
- EPS
- +69.0%
- Free cash flow
- −97.8%
Quarter to June 2026, against a year earlier
Follow MRKR
Alert me
MARKER THERAPEUTICS, INC. (MRKR) Altman Z-score
MARKER THERAPEUTICS, INC.'s Altman Z-score for fiscal 2025 is −28.68, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −28.68 | (4.74) |
| FY2024 | −23.94 | 3.90 |
| FY2023 | −27.84 | (9.84) |
| FY2022 | −18.00 | (10.31) |
| FY2021 | −7.69 | 2.61 |
| FY2020 | −10.30 | (34.59) |
| FY2019 | 24.29 | 15.23 |
| FY2018 | 9.06 | 43.43 |
| FY2017 | −34.37 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.88 | — | 1.06 | |
| Retained earnings / total assets | (24.08) | — | −33.71 | |
| EBIT / total assets | (0.68) | — | −2.23 | |
| Market value of equity / total liabilities | 10.03 | — | 6.02 | |
| Sales / total assets | 0.19 | — | 0.19 | |
| Altman Z-score | Distress zone | −28.68 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −69.50 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| VAXX Vaxxinity, Inc. compare | 3.3× |
| NEUP Neuphoria Therapeutics Inc. compare | −7.5× |
| ATYR aTyr Pharma, Inc. compare | −9.3× |
| KYNB Kyntra Bio Inc compare | −20.3× |
| ADAPY Adaptimmune Therapeutics PLC compare | −23.3× |
| MRKR MARKER THERAPEUTICS, INC. | −28.7× |
| PLUR Pluri Inc. compare | −30.4× |
| CTXR Citius Pharmaceuticals, Inc. compare | — |
| ABOS Acumen Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets